Saffron does lower blood pressure, just not enough to matter

Saffron has attracted research interest for its possible benefits in metabolic disease, and blood pressure is one of the most consequential numbers in health, feeding directly into heart attack and stroke risk. Supplements that claim to lower blood pressure are easy to sell and hard to verify, so pooling the trial evidence matters. The question this review set out to answer was simple: when saffron is tested against control conditions in randomised trials, does blood pressure actually move, and by how much? The size of the effect, not just its existence, determines whether it is worth anything to a buyer.

The authors systematically searched Scopus, Embase and the Cochrane Library for randomised controlled trials of saffron supplementation with blood pressure outcomes in adults, covering studies published up to March 2021. The initial search returned 182 publications, of which eight randomised controlled trials met the criteria for inclusion. Results were combined as weighted mean differences in systolic and diastolic blood pressure, and the team also ran a dose-response analysis to see whether effects varied with how much saffron was taken and for how long.

Saffron supplementation produced a statistically significant reduction in systolic blood pressure of 0.65 mmHg and in diastolic blood pressure of 1.23 mmHg compared with control. The diastolic effect followed a non-linear pattern depending on the duration of supplementation. Both findings cleared the bar for statistical significance, but the authors are unusually direct about the practical picture: the hypotensive effects were small and may not reach clinical importance. In other words, the signal is real in the data but modest in the body.

This review extends earlier work suggesting favourable influences of saffron on metabolic disease by putting a number on its blood pressure effect, and that number is the story. A statistically significant result from pooled trials can still be too small to change anyone's health, and this is a textbook example. Open questions include whether particular doses, longer durations or specific groups of adults respond more strongly, since the duration-dependent pattern hints the effect is not uniform. Larger trials with standardised dosing would be needed to settle that.

The useful knowledge here is the distinction between an effect that exists and an effect that matters. Saffron does appear to nudge blood pressure downward in trials, but a drop of roughly one point on either reading is far below what anyone concerned about their blood pressure needs. This is a reason to read supplement claims with the effect size in mind, not just the word significant. Anyone with genuinely raised blood pressure has far better-evidenced options to discuss with a clinician than a spice extract.